Table 1.
Demographic and clinical characteristics in patients with Crohn’s disease of the pouch
| Factor | Total (N =12) |
|---|---|
| Age at ulcerative diagnosis, years | 25.0 ± 11.5 |
| Mean age of patients, years | 41.0 ± 12.1 |
| Recent body mass index, kg/m2 | 23.7 ± 4.7 |
| Body mass index before vedolizumab use, kg/m2 | 23.2 ± 4.2 |
| Mean age of pouch duration, years | 12.0 ± 9.7 |
| Smoking, n (%) | 3.0 (25.0) |
| Excessive alcohol use, n (%) | 0 |
| Family history of colon cancer, n (%) | 0 |
| Family history of IBD, n (%) | 0 |
| Duration of vedolizumab use, months | 12.2 ± 6.4 |
| Phenotype of disease, n (%) | |
| Fibrostenotic | 6.0 (50.0) |
| Inflammatory | 6.0 (50.0) |
| Pouch type, n (%) | |
| J | 11.0 (91.7) |
| S | 1.0 (8.3) |
| Stage of pouch surgery, n (%) | |
| 1 | 1.0 (8.3) |
| 2 | 7.0 (58.3) |
| 3 | 4.0 (33.4) |
| Presence of extra-intestinal manifestations, n (%) | 3.0 (25.0) |
| Primary sclerosing cholangitis, n (%) | 0 |
| Mesalamine use pre vedolizumab, n (%) | 5.0 (41.7) |
| Concurrent vedolizumab and mesalamine use, n (%) | 3.0 (25.0) |
| Oral budesonide use pre vedolizumab, n (%) | 6.0 (50.0) |
| Concurrent vedolizumab and oral budesonide use, n (%) | 4.0 (33.3) |
| Prednisone use pre vedolizumab, n (%) | 4.0 (33.3) |
| Concurrent vedolizumab and prednisone use, n (%) | 2.0 (16.7) |
| Anti-TNF agent use pre vedolizumab, n (%) | 8.0 (66.7) |
IBD, inflammatory bowel disease; TNF, anti-tumor necrosis factor.